Conditioning Regimens Costs of Allogeneic Hematopoietic Cell Transplantation Using Reduced Intensity

Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graftversus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p 5 .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n 5 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) andaccountingmethodologies. Useofunrelated/ alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs. The Oncologist 2014; 19:639–644 Implications for Practice: This study from two large centers describes the profile and predictors of costs of reduced intensity conditioning (RIC) hematopoietic cell transplantation. Results indicate comparable costs between two centers with different practice patterns. Identification of optimum donors with favorable cost-benefit ratio and interventions to prevent complications suchas graft-versus-hostdiseasemayyield clinical and financial benefits. A commitment to lowering costswhilepreservingquality of care is essential in the current environment, especially for RIC transplants. These transplants are done mainly for the older population, amajority of whommay be prone to insufficient coverage and declining reimbursements byMedicare.The study also underscores the need for collection of resource utilization data in a prospective fashion with clinical studies.

[1]  B. Sandmaier,et al.  Costs of Second Allogeneic Hematopoietic Cell Transplantation , 2013, Transplantation.

[2]  M. Perales,et al.  Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? , 2013, Blood.

[3]  T. Arneson,et al.  Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation in the United States: A Study Using a Large National Private Claims Database , 2012, Bone Marrow Transplantation.

[4]  P. Armand,et al.  The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. , 2012, Biology of Blood and Marrow Transplantation.

[5]  M. Remberger,et al.  Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation , 2012, Bone Marrow Transplantation.

[6]  S. Mineishi Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go. , 2011, JAMA.

[7]  P. Hari,et al.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.

[8]  J. Wingard,et al.  Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. , 2011, Blood.

[9]  J. Sierra,et al.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Sepkowitz,et al.  Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated , 2009, Bone Marrow Transplantation.

[11]  D. Zahrieh,et al.  Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  D. Zahrieh,et al.  Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy , 2007, Bone Marrow Transplantation.

[13]  M. Remberger,et al.  Costs of Allogeneic Hematopoietic Stem Cell Transplantation , 2006 .

[14]  I. Durand-zaleski,et al.  Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia , 2005, Bone Marrow Transplantation.

[15]  S. Chevret,et al.  PREDICTING THE COSTS OF ALLOGENEIC SIBLING STEM-CELL TRANSPLANTATION: RESULTS FROM A PROSPECTIVE, MULTICENTER, FRENCH STUDY , 2004, Transplantation.

[16]  H. Sengeløv,et al.  Haematopoietic stem cell transplantation with non‐myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution , 2004, British journal of haematology.

[17]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[18]  T. Gooley,et al.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. , 2003, Blood.

[19]  M. Remberger,et al.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. , 2002, Blood.

[20]  E. Bass,et al.  Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Welch,et al.  Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. , 1989, The New England journal of medicine.

[22]  S. Goodman,et al.  Factors influencing third party payer costs for allogeneic BMT. , 1993, Bone marrow transplantation.